Terumo (TSE: 4543) announced that it has launched a global therapeutic interventional oncology team, effective April 1, 2021. Leuven, Belgium-based Terumo said in a news release that team’s introduction reflects its aspiration to be a global leader in the interventional oncology space by focusing on improving quality of life and survival. Team members work in […]
Immunotherapy
TriSalus, University of Texas to collaborate on solid tumor treatment study
TriSalus Life Sciences and the University of Texas today announced a collaboration to evaluate the treatment of solid tumors. The Texas MD Anderson Cancer Center and TriSalus will collaborate on treatments for tumors of the pancreas and liver by integrating interventional delivery of SD-101, an investigational toll-like receptor 9 (TLR9) agonist, in combination with checkpoint […]
UroGen Pharma raises $75M
UroGen Pharma (NSDQ:URGN) announced today that it entered into a funding agreement with RTW Investments worth $75 million. Princeton, N.J.-based UroGen’s agreement with RTW will see the biopharmaceutical company receive $75 million in upfront cash in return for tiered, future cash payments based on aggregate worldwide annual net product sales of Jelmyto (mitomycin) for pyelocalyceal […]
Bicara Therapeutics launches with $40M investment
Bicara Therapeutics announced today that it has launched with a $40 million investment from Biocon Limited. Cambridge, Mass.-based Bicara’s financing is earmarked for the advancement of its pipeline of first-in-class bifunctional antibodies developed between an engineering team in Bangalore, India, and the Cambridge-based executive team, according to a news release. Bicara’s pipeline includes tumor-targeted antibodies […]
Takeda to acquire T-cell engager therapy maker Maverick Therapeutics for $525M
Takeda Pharmaceutical (NYSE:TAK) announced that it is acquiring Maverick Therapeutics in a deal worth up to $525 million. Osaka, Japan-based Takeda exercised its option to acquire Maverick and its T-cell engager Cobra platform and development portfolio, including multiple solid tumor treatments in various clinical stages. Following the closing of the deal, Maverick employees will join […]
Janux Therapeutics raises $56M Series A for T cell engager tech
Janux Therapuetics announced today that it closed a $56 million Series A financing as it develops its T cell engager technology. Avalon Ventures led the financing round, while new investors OrbiMed and RA Capital Management joined in. Additionally, existing investors Bregua and Correlation Ventures participated. OrbiMed partner Dr. Peter Thompson and RA Capital Management partner […]
OncoSec announces positive results in metastatic melanoma case study
The International Journal of Surgery Case Reports has published a case study on the use of the humanized antibody Keytruda (pembrolizumab) and tavokinogene telseplasmid (TAVO) from OncoSec (NSDQ:ONCS) for treating metastatic melanoma. The study involved a patient with stage IIB, pT3b melanoma who initially underwent tumor resection but experienced regional recurrence and later disease progression […]
Inovio to scale up production of smart delivery device for potential COVID-19 vaccine
Inovio Pharmaceuticals (NSDQ:INO) announced that it received $71 million from the U.S. Defense Dept. to support its Cellectra 3PSP smart device. Funding from the DoD is set to support large-scale manufacturing for the Cellectra 3PSP and the procurement of Cellectra 2000 devices, which are used to deliver Inovio’s INO-4800 COVID-19 vaccine candidate directly into the skin. […]
MIT researchers think they’ve found a way to get more particles through a syringe
Researchers at the Massachusetts Institute of Technology (MIT) are touting a computational model that could prevent microparticle clogging during injections. Microparticles, which are about the size of a grain of sand, can be difficult to inject if they get clogged in a typical syringe. The research team at MIT developed this new model that determines […]
AbbVie gains U.S. nod for $63B Allergan takeover
Pharmaceutical giant AbbVie (NYSE:ABBV) has won U.S. antitrust approval for its purchase of Allergan (NYSE:AGN) for $63 billion in cash and stock. The purchase is seen as a hedge against the impending expiration of U.S. patents on AbbVie’s blockbuster drug, Humira. North Chicago-based AbbVie announced the deal in June 2019, but ran up against U.S. Federal Trade Commission […]
